HAT and HDAC activity can be altered by mutation, overexpression, or translocation, disrupting the acetylation-deacetylation balance and consequently contributing to cancer hallmarks; these epigenetic changes have been observed in leukaemia and prostate, breast, colorectal, and ovarian cancers [17, 13]. The gene discussed is HDAC9; the disease is cancer.